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Abstract
Aims Safety and tolerability of prolonged supplementation with a vitamin D, calcium and leucine-enriched whey protein 
medical nutrition drink (WP-MND) was evaluated in sarcopenic older adults.
Methods A 13-week double-blinded, randomized, isocaloric placebo-controlled trial (PROVIDE study; n = 380) was 
extended with a voluntary 13-week open-label extension (OLE). OLE participants were randomized to receive daily 1 or 2 
servings of WP-MND (21 g protein, 3 g leucine, 10 µg vitD and 500 mg calcium per serving). Gastro-intestinal tolerability, 
kidney function and serum levels of calcidiol, parathyroid hormone (PTH) and calcium were evaluated at week 0, 13 and 26.
Results and discussion In response to the high daily protein intake (median1.5; IQR: 1.3, 1.7 g/kg BW/day), the estimated 
glomerular filtration rate (eGFR) increased in the test group during the RCT (p = 0.013). The same trend was observed for 
those participants with moderate chronic kidney disease. During OLE no eGFR change was observed in any of the groups. 
Serum calcidiol and calcium reached a plateau after 13-week WP-MND supplementation. As expected, PTH significantly 
changed in the opposite direction, decreasing during RCT in the test group (T vs C: p < 0.001) and during OLE in former con-
trol groups. During RCT, 20/366 participants with normal baseline calcidiol reached levels ≥ 100 nmol/L (T: n = 18; C: n = 2) 
and 6 developed albumin-corrected calcium levels > 2.55 mmol/L (T: n = 3; C: n = 3), without associated adverse events.
Conclusion A 6 months intervention with up to 2 servings of WP-MND did neither result in kidney function deterioration 
nor symptoms of vitamin D or calcium toxicity. The product was overall well tolerated.
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Introduction
Sufficient dietary intake of protein, and an adequate vitamin 
D and calcium status has been proposed as a way to attenuate 
age-related loss of muscle and bone [1–8]. This is especially 
important for frail, sarcopenic and osteoporotic older adults 
who are at risk of falls, fractures and subsequent hospitaliza-
tion or institutionalization [9–11]. The European Society for 
Clinical Nutrition and Metabolism (ESPEN), the European 
Union Geriatric Medicine Society (EUGMS), and the Euro-
pean Society for Clinical and Economic Aspects of Osteo-
porosis and Osteoarthritis (ESCEO) recommend a protein 
intake of 1.0–1.2 g protein/kg bodyweight (BW)/day (d) for 
healthy older individuals and 1.2–1.5 g/kg BW/day for geriat-
ric patients with acute and/or chronic diseases [7, 9, 12]. The 
Institute of Medicine in the USA and ESCEO recommend 
a daily intake of 800 IU (= 20 µg) vitamin  D3 for people of 
71 years and older to sustain 25-hydroxyvitamin D (calcidiol) 
levels above 50 nmol/L [5, 7, 13–15]. Calcidiol is the precur-
sor of the active, but short-lived 1,25-hydroxyvitamin D (cal-
citriol), and represents an integrated marker of vitamin D sta-
tus as a result of endogenous synthesis from sun exposure and 
dietary intake [5]. The recommended daily allowance (RDA) 
for calcium for people of 71 years and older is 1200 mg/day 
[5]. Despite the recommendations above, insufficient intake of 
protein, vitamin D and calcium is still common in community-
dwelling older adults [16, 17]. This may also partly explain 
the observed 45% prevalence of vitamin D deficiency, i.e. cal-
cidiol < 50 nmol/L, in a large cohort of community-dwelling 
older (≥ 65 years) individuals [18].
Previously, an intervention with a vitamin D, calcium and 
leucine-enriched whey protein medical nutrition drink was 
shown to enhance muscle mass and improve lower-extremity 
function in sarcopenic older adults [19]. To obtain these ben-
eficial effects, two servings of the medical nutrition drink 
and thereby high amounts of protein (42 g), leucine (6 g), 
vitamin D (40 µg) and calcium (1000 mg) per day were con-
sumed on top of the regular diet. However, this may cause 
safety concerns in this vulnerable older target population 
with regard to kidney function and potential vitamin D or 
calcium toxicity. Older adults experience kidney function 
decline with age [20] and those with moderate or severe 
chronic kidney disease are advised to restrict protein intake 
and/or have their kidney function monitored on a regular 
basis [7, 9, 12]. Vitamin D or calcium toxicity related hyper-
calcemia may facilitate the formation of kidney stones and 
calcification of soft and vascular tissues, and result in acute 
symptoms such as nausea, vomiting, increased thirst and 
depression [21].
The aim of this post-hoc evaluation was to determine the 
effect of 6 months supplementation with a vitamin D, cal-
cium and leucine-enriched whey protein medical nutrition 
drink (WP-MND) on kidney function and on vitamin D, 
PTH and calcium levels in sarcopenic older adults. For this 
purpose, we extended the 13-week randomized placebo-
controlled trial [19], with a subsequent voluntary 13-week 
open-label study period with WP-MND supplementation in 
both the former test and control groups. In addition, general 
safety was evaluated with parameters of liver function and 
registration of adverse events and tolerability was evaluated 
by a questionnaire addressing symptoms of gastrointestinal 
discomfort.
Methods
Participants
As described in detail before [19, 22], participants were 
recruited from 18 study centers in 6 European countries. 
Older adults (≥ 65  years) were eligible when they suf-
fered from sarcopenia, defined as low skeletal muscle mass 
index (SMI) combined with mild to moderate limitations 
in physical performance (for definitions applied see refer-
ence [19]). People with liver or kidney failure were excluded 
from participation. Known kidney failure was defined in 
the published protocol as estimated glomerular filtration 
rate (eGFR) below 30 mL/min/1.73 m2, what means that 
participants with moderate chronic kidney disease (eGFR 
between 30 and 60) were eligible for participation in the 
study. For this group, Bauer et al. recommend that they 
adhere to general protein recommendations for older people 
(1.0–1.5 g protein/kg BW/day), but have their GFR moni-
tored twice a year [9]. Other exclusion criteria relevant were: 
(a) intake of a high protein diet 3 months before start of 
or during the study, (b) intake of a protein- or amino acid- 
containing nutritional supplement 3 months before start of 
or during the study, (c) consumption of more than 22 µg/
day vitamin D from vitamin supplement use, (d) consump-
tion of 11.25–22 µg vitamin D daily from vitamin supple-
ment use in combination with a serum calcidiol concentra-
tion ≥ 50 nmol/L, (e) consumption of more than 500 mg 
calcium daily from mineral supplement use.
Study design
The 13-week double-blinded RCT (known as the PROVIDE 
study) involved consumption of 2 servings of a vitamin D, 
calcium and leucine-enriched, whey protein medical nutri-
tion drink (WP-MND) in the test group or 2 servings of an 
iso-caloric drink with only carbohydrates, fat and some trace 
elements in the control group [19]. This RCT was extended 
with a 13-week open-label extension (OLE) study period. 
Participants in the RCT who volunteered to participate in 
the OLE part of the study, were randomized to receive either 
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1 or 2 servings of the WP-MND (FortiFit, Nutricia N.V., 
the Netherlands). One serving of WP-MND contained 21 g 
total protein, including 20 g whey protein and 3 g total leu-
cine, 9 g carbohydrates, 3 g fat, 800 IU (20 µg) vitamin  D3, 
500 mg calcium, and a mixture of vitamins, minerals and 
fibers (for detailed composition see online supplementary 
material—Supplemental Table 1 of Bauer et al. [19]). The 
one-serving group took the WP-MND before breakfast. In 
the two-serving group, the regimen was the same as in the 
intervention group of the RCT, i.e. before breakfast and 
lunch [19].
Outcome measures
Parameters were assessed prior to the RCT (baseline RCT), 
at the end of the RCT, which was also the start of the OLE 
part of the study (week 13, Baseline OLE), and after the 
OLE study period (week 26). For determination of blood 
parameters, approximately 25.5 mL of venous blood was 
obtained at each visit. Blood samples in which creatinine 
(µmol/L), calcidiol (nmol/L), parathyroid hormone (PTH, 
pmol/L), calcium (mmol/L) and albumin (g/L) were deter-
mined, were left at room temperature for 30 min and then 
centrifuged. Aliquots of serum were stored at −  20 or 
– 80 °C until analysis. These serum samples were analyzed 
at the Reinier de Graaf Groep medical laboratory, Delft, the 
Netherlands. Blood samples obtained for determination of 
the other parameters were processed and determined at the 
local laboratories on site, according to local procedures.
Kidney function
Kidney function was defined by the estimated glomerular 
filtration rate (eGFR, mL/min/1.73 m2) that was calculated 
with serum creatinine (Creat, µmol/L), using the Chronic 
Kidney Disease Epidemiology (CKD-EPI) Equation as 
described by Levey et al. [23]. Briefly, the CKD-EPI equa-
tion includes log [Creat] (modeled as a 2-slope linear spline 
with sex-specific 0.7 mg/dL in women and a 0.9 mg/dL in 
men), and gender, race, and age on a natural scale.
Vitamin D and calcium metabolism
Analytical testing for total serum calcidiol was performed 
using chemiluminescense micro-particulate immunoassay 
(Abbott Laboratories, Wiesbaden, Germany). To determine 
the effects of changes in the serum calcidiol on vitamin D 
metabolism, serum PTH and calcium were determined as 
well. Serum intact PTH concentrations were measured in 
serum using an ELISA [Intact parathyroid hormone, MD 
Biosciences Inc., St. Paul, MN 55108], with an intra-assay 
CV of 3.4%. For albumin-corrected calcium, total serum cal-
cium and albumin were measured by an automated system 
[Instrumentation Laboratories UK Ltd, Cheshire, UK]. The 
intra-assay CV for serum calcium and albumin was 1.7% 
and 1.8%, respectively. Serum calcium (Ca) normally ranges 
between 2.15 and 2.55 mmol/L [24, 25]; therefore, hyper-
calcemia was defined as [Ca] > 2.55 mmol/L [25]. Serum 
calcium was adjusted for albumin according to the equation 
described by James et al. [26]:
In participants with calcidiol levels ≥ 100 nmol/L at base-
line or during the study, serum calcium levels and adverse 
effects were closely evaluated.
General safety and gastrointestinal tolerability
Liver function was assessed at the local laboratories by 
determination of ALanine AminoTransferase (ALAT, U/L), 
ASparate AminoTransferase (ASAT, U/L), alkaline phos-
phatase (U/L), and gamma-Glutamyl Transpeptidase (ɣ-GT, 
U/L). Number and type of adverse events were registered. 
An adverse event was defined as any untoward medical 
occurrence in a clinical trial participant who was admin-
istered a study product, not necessarily implying a causal 
relationship with the intervention. The occurrence of adverse 
events was also checked between visits with intermittent 
phone calls. Gastrointestinal (GI) tolerability was assessed 
using a GI questionnaire at baseline, after 13 weeks and 
after 26 weeks of intervention. This questionnaire covered 
a range of GI symptoms: nausea, belching, feeling of full-
ness, vomiting, abdominal distension, flatulence, diarrhoea, 
constipation, dry mouth and thirst with a four-point scale 
(absent/mild /moderate/severe).
Statistical analysis
All the analysis of the main RCT paper [19] were done on 
the intention to treat (ITT) data set, while the safety and 
tolerability evaluation of the current paper was performed 
on the AST data set (n = 379 subjects), which excludes one 
subject in the control group who was randomized but did not 
start the intervention.
Normally distributed data were described as mean (SD or 
range) and analysed using the two-sample and paired t test 
for between and within-group differences, respectively. Not 
normally distributed data were described as median (IQR 
or range) and analysed using the Mann–Whitney test for 
between-group differences and the Wilcoxon Signed-Rank 
test for within-group changes. A p value < 0.05 indicates a 
significant difference between groups. All statistical analyses 
were performed using SAS software (version 9.4; SAS, Inc, 
Cary, NC).
Adjusted [Ca] = [total Ca] + 0.02 ∗ (40 − [albumin])
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Results
Participants flow (Fig. 1)
At the end of the 13-week RCT, 233 participants in the PRO-
VIDE study agreed to participate in the OLE sequel of the 
study (test (T): n = 103; control (C): n = 130). 133 subjects 
were randomized into the 1-serving groups (CT1 and TT1) 
and 100 subjects were randomized into the 2-serving groups 
(CT2 and TT2). At the end of the OLE study, 214 partici-
pants completed the study (former T group receiving 1 serv-
ing of WP-MND during OLE (TT1): n = 57, former T group 
receiving 2 serving of WP-MND during OLE (TT2): n = 39, 
former C group receiving 1 serving of WP-MND during 
OLE (CT1): n = 72, former C group receiving 2 serving of 
WP-MND during OLE (CT2): n = 46), and 19 participants 
exited the study before week 26.
Characteristics of the study population
Baseline characteristics of the RCT population are shown 
in the paper by Bauer et al. [19] and in Table 1 together 
with week 13 baseline characteristics of the 4 different OLE 
groups. Characteristics were not different between groups, 
neither at baseline for the RCT nor at baseline for the OLE 
study period, apart from a difference in total protein intake, 
serum calcidiol and PTH at the start of the OLE study period 
due to prior intervention in the RCT, which excludes poten-
tial selection bias in the OLE extension.
Protein intake and kidney function
During the RCT, supplementation with WP-MND led to a 
significant increase in median total protein intake from 1.0 
(IQR: 0.9, 1.2) g/kg BW/day to 1.5 (IQR: 1.3, 1.7) g/kg 
BW/day in the test group (p < 0.001), with no change in the 
control group (T vs. C: p < 0.001). Median protein intake 
(g/kg BW/day) increased in the former RCT control groups 
during the OLE study period from 0.9 (IQR: 0.8, 1.1) to 1.3 
(IQR: 1.1, 1.5) in the CT1 (p < 0.001) and to 1.4 (IQR: 1.3, 
1.7) g/kg BW/day in the CT2 group (p < 0.001). In the TT1 
group that consumed one serving of WP-MND during the 
OLE study period after consumption of 2 servings during 
the RCT, median protein intake decreased from 1.5 (IQR: 
1.3, 1.7) to 1.2 (IQR: 1.1, 1.4) g/kg BW/day (p < 0.001) ver-
sus no change in the TT2 group (TT1 vs. TT2: p < 0.001).
Fig. 1  Participants flow. WP-
MND, a vitamin D and leucine-
enriched whey protein medical 
nutrition drink; T, test group 
during RCT; C, Control group 
during RCT; OLE, open-label 
extension; TT1, former RCT 
Test group receiving 1 serving 
of WP-MND during OLE; 
TT2, former RCT Test group 
receiving 2 servings of WP-
MND during OLE; CT1, former 
RCT Control group receiving 
1 serving of WP-MND during 
OLE; CT2, former RCT Control 
group receiving 2 servings of 
WP-MND during OLE
n=158 completed RCT 
n=46 completed 
OLE (CT2)
n=1 excluded from 
AST set (did not take 
the study product)
n=1240 assessed for 
eligibility
n=860 not included for 
reasons specified elsewhere[19]
n=380 
randomized in 
RCT – ITT set [19]
n=184 received 
2 servings of WP-MND 
(AST set)
n=195 received 
2 servings of control 
product (AST set)
n=40 dropout RCT 
for reasons specified 
elsewhere [19]
n=38 dropout RCT 
for reasons specified 
elsewhere [19]
n=103 
randomized in 
OLE period
n=144 completed RCT
n=43 received 
2 servings 
WP-MND (TT2)
n=60 received 
1 serving of 
WP-MND (TT1)
n=73 received 
1 serving of 
WP-MND (CT1)
n=57 received 
2 servings of 
WP-MND (CT2)
n=130 
randomized in 
OLE period
n=57 completed 
OLE (TT1)
n=39
OLE (TT2)
n=72 completed completed 
OLE (CT1)
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The study population had a median eGFR of 77 (IQR: 63, 
87) mL/min/1.73 m2 at baseline, prior to the RCT. 13-week 
supplementation with 2 servings of the WP-MND during 
the RCT led to a small increase in eGFR in the test group 
(median change 1.0 (IQR: − 2.8, 4.2) mL/min/1.73 m2; 
p = 0.013) versus no significant change in the control group 
(median change − 1.1 (IQR: − 4.9, 2.8) mL/min/1.73 m2; 
p = 0.067)(T vs. C: p = 0.002) (Fig. 2a). No change in eGFR 
was observed during the OLE part of the study (Fig. 2b). 
Some of the participants (T: n = 36 and C: n = 39) had an 
eGFR between 30 and 60 mL/min/1.73 m2 at baseline, before 
the start of the RCT, which is defined as moderate chronic 
kidney disease (CKD). In this vulnerable subgroup, the same 
trend in eGFR was observed as in the total study popula-
tion. During the RCT, eGFR increased in participants with 
moderate CKD at baseline in the test group from median 52 
(IQR: 48.1, 56.2) to 56.2 (IQR: 46.5, 63.8; p = 0.007) mL/
min/1.73 m2 vs. no change in the control group (T vs. C: 
NS). No further change was observed during OLE within or 
between the moderate CKD subgroups.
Table 1  Baseline (week 0) characteristics of RCT participants (n = 279, AST data set) and baseline (week 13) characteristics of participants in 
open-label extension of the study (OLE) (n = 233, AST data set)
CT1, former RCT Control group receiving 1 serving of WP-MND during OLE; CT2, former RCT Control group receiving 2 servings of WP-
MND during OLE; TT1, former RCT Test group receiving 1 serving of WP-MND during OLE; TT2, former RCT Test group receiving 2 serv-
ings of WP-MND during OLE
Statistic Total RCT 
(n = 379)
Week 0 (baseline RCT) Week 13 (baseline OLE)
Control 
(n = 195)
Test (n = 184) Total OLE 
(n = 233)
RCT control (n = 130) RCT Test (n = 103)
CT1 (n = 73) CT2 (n = 57) TT1 (n = 60) TT2 (n = 43)
Age (years) Mean 
(SD)
77.7 (6.9) 78.1 (7.0) 77.3 (6.7) 77.4 (6.7) 77.8 (6.7) 78.5 (6.9) 75.6 (6.1) 77.4 (7.2)
Sex (male) n (%) 131 (34.6) 67 (34.4) 64 (34.8) 90 (38.6) 27 (37.0) 25 (43.9) 25 (41.7) 13 (30.2)
Living indepen-
dently
n (%) 328 (86.5) 166 (85.1) 162 (88.0) 209 (89.7) 65 (89.0) 47 (82.5) 58 (96.7) 39 (90.7)
MNA-SF, score Mean 
(SD)
13.1 (1.3) 13.1 (1.5) 13.2 (1.2) 13.2 (1.2) 13.2 (1.2) 13.1 (1.4) 13.4 (1.0) 13.3 (1.1)
Weight (kg) Mean 
(SD)
69.8 (11.2) 69.5 (10.9) 70.2 (11.6) 72.1 (10.7) 71.6 (9.2) 70.8 (11.9) 73.5 (9.5) 73.0 (12.9)
BMI (kg/m2) Mean 
(SD)
26.1 (2.7) 26.2 (2.8) 26.0 (2.5) 26.6 (2.7) 26.9 (2.6) 26.3 (3.0) 26.7 (2.6) 26.5 (2.7)
Total protein 
intake (g/kg 
BW/day)
Median 
(IQR)
1.0 (0.8,1.2) 1.0 (0.8,1.2) 1.0 (0.9,1.2) 1.1 (0.9,1.5) 0.9 (0.8,1.1) 0.9 (0.8,1.0) 1.5 (1.3,1.7) 1.5 (1.3,1.7)
Total energy 
intake (kcal/
day)
Median 
(IQR)
1653 
(1411,1964)
1612 
(1404,1919)
1698 
(1423,2028)
1880 
(1606,2208)
1907 
(1587,2163)
1815 
(1603,2011)
1964 
(1601,2275)
1856 
(1638,2372)
Dietary vitamin 
D intake (µg/
day)
Median 
(IQR)
2.0 (1.0, 4.0) 1.9 (0.9, 3.7) 2.0 (1.1, 4.1) 2.1 (1.0, 4.3) 2.6 (1.1, 6.5) 1.9 (0.9, 4.1) 2.2 (1.0, 3.8) 2.0 (1.0, 4.8)
Serum calcidiol 
(nmol/L)
Median 
(IQR)
48.0 (34.0,66.0) 49.0 (34.0,65.0) 48.0 (33.0,66.0) 64.0 (39.0,80.0) 43.0 (30.0,58.5) 41.0 (28.0,57.0) 81.0 (69.0,96.0) 77.0 (68.0,88.0)
PTH (pmol/L) Median 
(IQR)
5.7 (4.2,7.7) 5.7 (4.2,7.5) 5.9 (4.2,8.1) 5.3 (3.8,7.4) 5.8 (4.5,7.7) 6.1 (5.2,8.2) 4.6 (3.6,6.9) 4.3 (3.4,5.7)
Calcium 
corrected 
for albumin 
(mmol/L)
Mean 
(SD)
2.3 (0.14) 2.31 (0.15) 2.29 (0.12) 2.31 (0.14) 2.30 (0.15) 2.30 (0.17) 2.33 (0.11) 2.33 (0.12)
Creatinine 
(µmol/L)
Mean 
(SD)
76.1 (21.7) 76.7 (21.7) 75.5 (21.8) 76.3 (20.3) 76.2 (18.7) 79.7 (21.0) 74.4 (21.3) 74.4 (20.9)
eGFR (mL/
min/1.73m2)
Mean 
(SD)
73.5 (15.9) 73.0. (16.4) 74.1 (15.4) 73.9 (15.6) 73.0 (15.4) 71.5 (15.8) 77.1 (14.4) 74.3 (17.2)
ALAT (U/L) Mean 
(SD)
20.2 (8.1) 20.1 (8.5) 20.2 (7.6) 23.1 (14.6) 23.4 (17.7) 20.9 (9.0) 25.7 (18.0) 22.3 (8.3)
ASAT (U/L) Mean 
(SD)
23.6 (6.4) 23.4 (6.7) 23.9 (6.1) 25.1 (14.5) 26.7 (23.7) 24.2 (6.8) 25.0 (8.0) 23.9 (6.0)
ALP (U/L) Mean 
(SD)
77.4 (25.2) 78.3 (27.6) 76.3 (22.3) 78.2 (28.5) 81.5 (40.0) 79.3 (22.5) 77.3 (23.0) 72.8 (18.1)
ɣ-GT (U/L) Mean 
(SD)
29.3 (30.9) 29.7 (30) 29.0 (31.9) 30.7 (32.5) 31.8 (28.2) 26.5 (20.5) 36.1 (50.2) 26.9 (16.9)
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Leucine intake
Based on the reported protein intake data and the estima-
tion that dietary protein contains on average 7.8% leucine 
[27], the total daily leucine intake from the diet and the 
WP-MND was calculated. The median baseline intake of 
leucine from the diet at the start of the RCT was estimated 
to be around 0.078 g/kg BW/day (1.0 g protein/kg BW/day). 
At week 13, leucine intake from the diet was estimated to 
be around 0.070 g/kg BW/day (0.9 g protein/kg BW/day) 
in 50% (median) and 0.086 g/kg BW/day (1.1 g protein/kg 
BW/day) in 75% (upper IQR) of the test group. The WP-
MND supplement contributed to an additional 6 g leucine 
per day, representing 0.086 g/kg BW/day based on a median 
bodyweight of 70 kg. In total, leucine intake in the WP-
MND group was 0.171 g/kg BW/day in 75% of subjects, 
which is well below the TUL for leucine of 0.5 g/kg BW/
day [28–30].
Vitamin D and calcium metabolism
After 13 weeks of intervention with 2 servings of the WP-
MND in the test group, a significant increase in median 
serum calcidiol (p < 0.001) was observed versus a signifi-
cant decrease (p < 0.001) in the control population (T vs. 
C: p < 0.001) (Fig. 3a). No further increase was observed 
in either of the former test groups (TT1 and TT2) during 
the OLE study period (13 vs. 26 weeks) (Fig. 3b). On the 
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Fig. 2  Estimated glomerular filtration rate (eGFR) in the RCT (a), 
and OLE population (b). Results are expressed as median (IQR). This 
figure shows the eGFR in the RCT population at baseline (week 0) 
and after intervention (week 13) with 2 servings of a vitamin D, cal-
cium and leucine enriched whey protein medical nutrition drink (WP-
MND) (Test) or Control product (Control) (a), and in the open-label 
extension (OLE) population at baseline (week 13) and after inter-
vention (week 26) with one or two servings of WP-MND) (b). CT1, 
former RCT Control group receiving 1 serving of WP-MND during 
OLE; CT2, former RCT Control group receiving 2 servings of WP-
MND during OLE; TT1, former RCT Test group receiving 1 serving 
of WP-MND during OLE; TT2, former RCT Test group receiving 2 
servings of WP-MND during OLE. #Significant difference in change 
between Test and Control groups. * Significant change within group
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Fig. 3  Serum levels of 25-hydroxy-vitamin D (calcidiol) in the RCT 
(a), and OLE population (b). Results are expressed as median (IQR). 
This figure shows the serum concentrations of calcidiol in the RCT 
population at baseline (week 0) and after intervention (week 13) with 
2 servings of a vitamin D, calcium and leucine enriched whey protein 
medical nutrition drink (WP-MND) (Test) or control product (Con-
trol) (a), and in the OLE population at baseline (week 13) and after 
intervention (week 26) with one or two servings of WP-MND (b). 
CT1, former RCT Control group receiving 1 serving of WP-MND 
during OLE; CT2, former RCT Control group receiving 2 servings 
of WP-MND during OLE; TT1, former RCT Test group receiving 
1 serving of WP-MND during OLE; TT2, former RCT Test group 
receiving 2 servings of WP-MND during OLE. #Significant differ-
ence in change between Test and Control groups. * Significant change 
within group
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other hand, a significant increase in calcidiol levels was 
observed in the participants who switched from the control 
product during the RCT to the test product in the OLE study 
period (both CT1, CT2: p < 0.001) and most in the group 
that received 2 servings of the WP-MND (CT1 vs. CT2: 
p < 0.001).
Fourteen participants had a serum calcidiol concentra-
tion ≥ 100 nmol/L at baseline, prior to the RCT (T: n = 6; 
C: n = 8). In 20 participants with normal calcidiol levels 
at baseline, calcidiol increased above 100  nmol/L dur-
ing the RCT (T: n = 18, C: n = 2). During the OLE study 
period, the number of participants with serum calcidiol lev-
els ≥ 100 nmol/L decreased in the former test groups (T: 
n = 20 → 16) and increased in the former control groups (C: 
n = 6 → 9). In 13 OLE participants (T: n = 10; C: n = 3) with 
calcidiol levels ≥ 100 at week 13, serum calcidiol increased 
further at week 26 (range of increase: 2–38 nmol/L), inde-
pendent of the number of servings.
During the RCT, serum levels of PTH decreased in 
the test group (p < 0.001) and increased in the control 
group (p = 0.006) (Fig. 4a). Serum levels of PTH did not 
change with continued supplementation of a WP-MND 
but decreased significantly in participants who switched 
from control to test product during the OLE study period 
(p < 0.001) (Fig. 4b).
During the RCT, the albumin-adjusted serum calcium 
concentration increased in the test group from 2.29 to 
2.33 mmol/L (p < 0.001) versus no change in the control 
group (mean: 2.31 mmol/L; T vs. C: p < 0.001) (Fig. 5a). 
During the OLE study period, calcium levels increased in the 
former control population (CT1: p = 0.017; CT2: p = 0.003) 
whereas no further increase was observed in the former test 
population (Fig. 5b). Although albumin-corrected calcium 
levels > 2.55 mmol/L were observed, the proportion of par-
ticipants with hypercalcaemia was not different between 
groups (Table 2). At baseline, 12 subjects already mani-
fested albumin-corrected calcium levels above 2.55 mmol/L 
(T: n = 3; C: n = 9). During the RCT, a similar number of 
subjects in the test and control group developed hypercal-
caemia (T: n = 3; C: n = 3), while 8 (T: n = 2; C: n = 6) of 
the 14 subjects with hypercalcemia at week 13 already had 
elevated levels at baseline. This suggests no direct associa-
tion between the development of hypercalcemia and sup-
plementation of WP-MND but may point to a surprisingly 
higher prevalence of hypercalcemia in this sarcopenic older 
population. In OLE extension with 2 servings per day (CT2), 
2 subjects maintained the elevated calcium levels and 3 new 
subjects were found with calcium levels above 2.55 mmol/L. 
In the OLE group taking 1 serving a day (CT1), 3 subjects 
maintained higher calcium levels, while 2 subjects with the 
elevation of calcium above 2.55 mmol/L were found. The 
presence of hypercalcemia at baseline or development of 
hypercalcemia during the study in any of the groups showed 
no connection to evolvement over time of PTH, calcidiol, 
creatinine, and eGFR.
At the start of RCT, none of the 14 participants with 
calcidiol levels above 100 nmol/L had albumin-corrected 
calcium levels above 2.55 mmol/L. At week 13 (end RCT 
and start OLE), 3 out of 26 participants with calcidiol above 
100 nmol/L (from the former test group) had albumin-cor-
rected calcium levels above 2.55 mmol/L. At week 26 (end 
OLE), 3 out of 25 participants had both levels elevated (1 
from the TT1, 1 from the TT2 and 1 from the CT2 group) of 
which for one of them (from the TT2 group) this was already 
the case at baseline OLE.
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Fig. 4  Serum levels of parathyroid hormone (PTH) in the RCT (a), 
and OLE population (b). Results are expressed as median (IQR). This 
figure shows the serum concentrations of PTH in the RCT population 
at baseline (week 0) and after intervention (week 13) with 2 servings 
of a vitamin D, calcium and leucine enriched whey protein medical 
nutrition drink (WP-MND) (Test) or Control product (Control) (a), 
and in the OLE population at baseline (week 13) and after inter-
vention (week 26) with one or two servings of WP-MND (b). CT1, 
former RCT Control group receiving 1 serving of WP-MND during 
OLE; CT2, former RCT Control group receiving 2 servings of WP-
MND during OLE; TT1, former RCT Test group receiving 1 serving 
of WP-MND during OLE; TT2, former RCT Test group receiving 2 
servings of WP-MND during OLE. #Significant difference in change 
between Test and Control groups. * Significant change within group
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General safety, vital signs
Parameters of liver function did not increase during the RCT 
or OLE study period and values were within the range of 
reference values (Table 1).
At baseline, heart rate was significantly higher in the 
test group compared to the control group (p = 0.011), but 
no significant changes in heart rate, systolic and diastolic 
blood pressure were observed between the two groups after 
13 weeks of intervention (Table 3 in Appendix). At OLE 
baseline (week 13), heart rate in TT1 was significantly lower 
compared to the TT2 group (p = 0.018), but no other signifi-
cant differences were found between the groups at week 26. 
Similarly, no significant differences were found in systolic or 
diastolic blood pressure between the different groups (CT1 
vs. CT2; TT1 vs. TT2; CT2 vs. TT2) during the OLE exten-
sion (Table 4 in Appendix).
Adverse events
During the RCT, a total of 557 adverse events were reported 
among 240 subjects. From those, 193 were assessed as being 
related to the study products, without a significant difference 
between the test group (46 subjects; 25.0%) and the control 
group (54 subjects; 27.7%) (p = 0.562). In the OLE study 
period, a total of 216 adverse events were reported among 
112 subjects. From those, 57 were assessed as being related 
to the study product. The number of subjects reporting one 
or more related adverse events was significantly higher in the 
TT2 group (9 subjects; 20.9%) compared to the TT1 group 
(only 3 subjects; 5%) (p = 0.026). Since other between-
groups comparisons did not show a significant difference 
(TT2 vs. CT2 and CT2 vs. CT1), there was no apparent dose-
relationship and the data did not point to any concern. The 
most commonly reported related adverse events were gastro-
intestinal (such as abdominal pain and nausea) or metabolic 
and nutritional disorders (such as hyperglycaemia). No 
treatment-related serious adverse events occurred during the 
RCT and OLE study periods. Moreover, no related adverse 
(serious or non-serious) events, including nephrolithiasis 
(kidney stones), were observed in participants with serum 
calcidiol levels ≥ 100 nmol/L or with albumin-adjusted cal-
cium levels > 2.55 mmol/L, at any of the time points.
Gastrointestinal tolerability
The incidence and the severity of the self-reported GI 
symptoms (nausea, belching, feeling of fullness, vomiting, 
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Fig. 5  Albumin-adjusted serum levels of calcium in the RCT (a), and 
OLE population (b). Results are expressed as mean (SD). This figure 
shows the albumin-adjusted serum concentrations of calcium in the 
RCT population at baseline (week 0) and after intervention (week 13) 
with 2 servings of a vitamin D, calcium and leucine enriched whey 
protein medical nutrition drink (WP-MND) (Test) or Control product 
(Control) (a), and in the OLE population at baseline (week 13) and 
after intervention (week 26) with one or two servings of WP-MND 
(b). CT1, former RCT Control group receiving 1 serving of WP-
MND during OLE; CT2, former RCT Control group receiving 2 serv-
ings of WP-MND during OLE; TT1, former RCT Test group receiv-
ing 1 serving of WP-MND during OLE; TT2, former RCT Test group 
receiving 2 servings of WP-MND during OLE. #Significant differ-
ence in change between Test and Control groups. * Significant change 
within group
Table 2  Prevalence (n, 
%) of hypercalcaemia 
(albumin corrected 
calcium > 2.55 mmol/L) during 
RCT and open-label extension 
of the study (OLE)
CT1, former RCT Control group receiving 1 serving of WP-MND during OLE; CT2, former RCT Control 
group receiving 2 servings of WP-MND during OLE; TT1, former RCT Test group receiving 1 serving of 
WP-MND during OLE; TT2, former RCT Test group receiving 2 servings of WP-MND during OLE
Control Test CT1 CT2 TT1 TT2
Baseline RCT (week 0) 9 (4.8%) 3 (1.7%) 3 (4.3%) 4 (7.7%) 2 (3.4%) 0 (0.0%)
End RCT/baseline OLE (week 13) 9 (5.8%) 4 (2.9%) 4 (5.6%) 2 (3.5%) 1 (1.7%) 1 (2.4%)
End OLE (week 26) 10 (8.7%) 1 (1.1%) 5 (6.9%) 5 (11.6%) 1 (1.8%) 0 (0.0%)
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abdominal distension, flatulence, diarrhoea, constipation, 
dry mouth and thirst) did not differ between the control and 
the test group at baseline or the end of the RCT (Table 5 in 
Appendix). Moreover, no difference was observed between 
the two groups with regards to the changes at week 13 rela-
tive to the baseline for any of the GI symptoms. The OLE 
study also showed no difference in the incidence or severity 
of the GI symptoms between the groups (CT1 vs. CT2; TT1 
vs. TT2; CT2 vs. TT2), except for diarrhoea which was sig-
nificantly lower in CT2 compared to CT1 (p = 0.01) (Table 6 
in Appendix).
Discussion
6-month intervention with up to 2 servings of this WP-MND 
in addition to a regular diet neither impaired kidney func-
tion nor caused vitamin D and/or calcium toxicity and is not 
related to impaired liver function and vital signs, increased 
gastro-intestinal intolerance or -adverse events.
Protein intake and kidney function
The consistent high protein intake in line with recommen-
dations, especially in participants receiving 2 servings of 
WP-MND throughout the entire 26-week study period (dur-
ing RCT and OLE), enabled evaluation of the effect of a 
prolonged high protein intake on kidney function.
Concerns regarding the adverse effect of a high protein 
diet on kidney function are related to glomerular hyperfil-
tration and hypertensive effects [31–33]. During the RCT, 
eGFR increased in the test vs. no change in the control group 
(p = 0.002). The same trend was observed in the subgroup of 
participants with moderate CKD at baseline. During OLE, 
no (further) change in eGFR was observed in any of the 
(sub)groups. The alteration of eGFR in response to a high 
protein diet is in line with observations by others and is 
thought to be an adaptive response to the protein feeding 
and not the development of CKD per se [31, 33, 34]. The 
observed plateau in eGFR after 13 weeks of treatment with 
2 servings of WP-MND during the OLE period, supports 
this notion of adaptation. Moreover, the observed increase 
and subsequent plateau of eGFR after 13 weeks of treat-
ment in older people with moderate CKD suggest that even 
those individuals still tolerate a high protein diet. However, 
caution is still warranted, and kidney function should be 
monitored on a regular basis in people on a high protein diet 
with moderate CKD, as recommended [7, 9, 12]. Further-
more, blood pressure did not change over time and was not 
different between groups, which supports the assumption 
that the observed increase of eGFR was not an indication of 
early kidney failure.
Vitamin D and calcium metabolism
Calcidiol levels increased with the intake of 2 servings of 
WP-MND, providing 40 µg vitamin D, and reached a plateau 
at ~ 80 nmol/L after 3 months of supplementation. Moreo-
ver, 1 serving of WP-MND providing 20 µg vitamin D also 
increased calcidiol levels after 3 months, although to a lesser 
extent (~ 70 nmol/L), hence suggesting a dose–response 
effect. When considering a baseline diet with a median vita-
min D intake of 2.0 (IQR: 1.0, 4.0) µg/day at the beginning 
of the RCT and 2.1 (IQR: 1.0, 4.3) µg/day at the begin-
ning of OLE (Table 1), the total intake of vitamin D did 
not exceed 50 µg/day. This amount is well below the TUL 
for vitamin D intake at 100 µg per day set by EFSA [35]. 
For adults, EFSA selected hypercalcemia as the indicator 
of vitamin D toxicity that may occur when plasma levels of 
calcidiol increase above 100 nmol/L [5, 15, 36–39]. In our 
study, some participants had calcidiol levels ≥ 100 nmol/L 
with or without hypercalcemia (albumin-corrected calcium 
levels > 2.55 mmol/L) at baseline or during the study. How-
ever, no causal relation was observed between high serum 
calcidiol and calcium levels and no related adverse events 
were reported. An explanation for high plasma calcidiol lev-
els may be an enhanced endogenous skin vitamin D produc-
tion following exposure to sunlight [40, 41] or clandestine 
consumption of vitamin D containing food supplements.
Although no relationship was observed between hyper-
calcidiol and hypercalcemia, the overall increase in serum 
calcium was significant but marginal in the test group during 
the RCT, and in the control group during OLE. This increase 
was observed to plateau after 3 months of supplementation 
with 2 servings of WP-MND. The total group average serum 
calcium level at baseline was 2.30 mmol/L (not different 
between groups), which is within the reference range of 
2.15–2.6 mmol/L [24]. Twelve participants had hypercalce-
mia at baseline of the RCT, which is a surprisingly higher 
prevalence than reported in other populations, such as in 
the community and hospital (0.2–4% [42, 43]). This war-
rants confirmation of potentially unknown hypercalcemia 
cases among the sarcopenic population in future research. 
The prevalence of hypercalcemia did not change during the 
course of the RCT and the OLE study periods, with some 
participants maintaining hypercalcemia and others devel-
oping hypercalcemia, independent of the treatment group. 
The presence or development of hypercalcemia could not 
be linked to clinically relevant safety indicators or adverse 
events. As expected, serum parathyroid hormone (PTH) 
levels decreased with the intake of the WP-MND. There-
fore, hyperparathyroidism was unlikely to be the cause of 
observed hypercalcemia. Another cause for hypercalcemia 
could be due to the calcium provided (1000 mg in 2 servings 
of WP-MND on top of the diet providing on average about 
1000 g/day of calcium), leaving a margin of 500 mg before 
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exceeding the TUL as established by EFSA [44]. However, 
the Panel considers that no relationship has been established 
between long-term calcium intakes at 2.5 g/day from diet 
and supplements and increased risk of nephrolithiasis.
General safety and gastrointestinal tolerability
There was no difference in the number and origin of the 
adverse events between test and (former) control groups. 
Most of the adverse events were gastrointestinal, but the inci-
dence and severity of gastrointestinal symptoms did not dif-
fer between the treatment groups. No potentially treatment-
related serious adverse events were observed. Moreover, 
no adverse (serious or non-serious) events were observed 
in participants with serum calcidiol levels ≥ 100 nmol/L 
or with albumin-adjusted calcium levels > 2.55 mmol/L, at 
any of the time points. Finally, vital signs did not change 
throughout the study, and parameters of liver function were 
within the reference range and did not increase in any of the 
groups during the RCT or OLE study period.
Strengths and limitations
The main strength of this investigation is the evaluation of 
the safety of an effective medical nutrition drink in a study 
group of sarcopenic older adults (n = 380) [19]. Detailed 
information was collected about the impact of 1–2 servings 
of WP-MND on protein intake, kidney function, vitamin 
D and calcium metabolism. Furthermore, participants with 
moderate CKD, supra-normal levels of calcidiol or hypercal-
cemia were separately analyzed and scrutinized for adverse 
effects. Another strength is that we observed a plateau after 
3-months of WP-MND supplementation for eGFR and 
plasma levels of calcidiol, calcium and PTH, suggesting 
that the study period was likely long enough to demonstrate 
that consumption of two servings of WP-MND is safe in the 
longer term. A study limitation may be that treatment groups 
were small during OLE, although observed effects point in 
the same direction as during the RCT. Another limitation 
may be that we did not determine plasma ammonia and insu-
lin resistance over time, which are indicative of short-term 
leucine toxicity and potential negative effects of leucine sup-
plementation in longer term [45]. Furthermore, eGFR should 
perhaps have been monitored over an even longer period to 
ensure that the observed increase in eGFR in the test popula-
tion just represented an adaptation to the high protein intake.
In conclusion, a 6-month intake of a vitamin D, calcium 
and leucine-enriched whey protein medical nutrition drink 
in addition to a regular diet does not impair kidney function 
or disturb vitamin D and calcium metabolism in sarcopenic 
older adults. Furthermore, WP-MND does not affect liver 
function and vital signs and is well tolerated by the gastro-
intestinal tract. In line with the protein recommendations, we 
do recommend monitoring of kidney function in consumers 
with moderate CKD [9]. For kidney protection in general, 
sufficient fluid intake is recommended for proper hydration 
[46].
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Appendix
See Tables 3, 4, 5, 6.
Table 3  Measured vital signs at baseline of the RCT study (week 0) and at the end of the RCT study (week 13) in the control and the test group
CT1, former RCT Control group receiving 1 serving of WP−MND during OLE; CT2, former RCT Control group receiving 2 servings of WP−
MND during OLE; TT1, former RCT Test group receiving 1 serving of WP−MND during OLE; TT2, former RCT Test group receiving 2 serv-
ings of WP−MND during OLE
*Significant difference between control and test; p value = 0.011 (t test)
Vital signs Statistic Week 0 (baseline RCT) Week 13 (end RCT, baseline OLE)
Control (n = 195) Test (n = 184) Control (n = 196) Test (n = 184)
Heart rate (bpm) Mean (SD) 69.2 (11.3) 72.1 (11.1)* 69.5 (11.2) 71.5 (10.3)
Systolic blood pressure (mmHg) Mean (SD) 141 (20.8) 137 (18.2) 138.8 (20.4) 134.8 (15.8)
Diastolic blood pressure (mmHg) Mean (SD) 76 (10.4) 75.6 (10.3) 76.4 (10.2) 74.7 (9.5)
Table 4  Vital signs at baseline of the open-label extension (week 13) and at the end of the OLE study period (week 26)
CT1, former RCT Control group receiving 1 serving of WP-MND during OLE; CT2, former RCT Control group receiving 2 servings of WP-
MND during OLE; TT1, former RCT Test group receiving 1 serving of WP-MND during OLE; TT2, former RCT Test group receiving 2 serv-
ings of WP-MND during OLE
* Significant difference between TT1 and TT2; p value = 0.018 (t test)
Vital signs Statistic Week 13 (baseline OLE) Week 26
RCT control (n = 130) RCT tests (n = 103) RCT control (n = 130) RCT tests (n = 103)
CT1 (n = 73) CT2 (n = 57) TT1 (n = 60) TT2 (n = 43) CT1 (n = 73) CT2 (n = 57) TT1 (n = 60) TT2 (n = 43)
Heart rate 
(bpm)
Mean (SD) 67.1 (10.9) 71 (11.3) 69.2 (11.5) 74.4 (9.7)* 67.8 (10.8) 69.6 (10.4) 70.4 (10.3) 73.4 (9.6)
Systolic blood 
pressure 
(mmHg)
Mean (SD) 142 (22.2) 135.5 (19) 135 (16.5) 134.1 (16.8) 138.1 (19) 132.5 (17.3) 138.2 (16.7) 134.5 (14.4)
Diastolic 
blood 
pressure 
(mmHg)
Mean (SD) 76.9 (10.1) 75.2 (9.1) 76.2 (10.5) 72.5 (8.8) 73.9 (11) 74 (9.7) 76 (9.1) 74.1 (9.4)
Table 5  Incidence of the 
gastrointestinal symptoms 
at baseline of the RCT study 
(week 0) and at the end of the 
RCT (week 13) in the test and 
the control group
CT1, former RCT Control group receiving 1 serving of WP-MND during OLE; CT2, former RCT Control 
group receiving 2 servings of WP-MND during OLE; TT1, former RCT Test group receiving 1 serving of 
WP-MND during OLE; TT2, former RCT Test group receiving 2 servings of WP-MND during OLE
GI symptoms Statistic Week 0 (baseline RCT) Week 13 (end RCT, baseline 
OLE)
Control (n = 195) Test (n = 184) Control (n = 195) Test (n = 184)
Nausea n (%) 21 (10.8%) 14 (7.6%) 15 (9.5%) 17 (11.9%)
Belching n (%) 48 (24.6%) 44 (23.9%) 36 (22.8%) 36 (25.2%)
Feeling of fullness n (%) 44 (22.6%) 39 (21.2%) 49 (31.0%) 48 (33.6%)
Vomiting n (%) 4 (2.1%) 4 (2.2%) 3 (1.9%) 1 (0.7%)
Abdominal distension n (%) 46 (23.6%) 45 (24.5%) 33 (20.9%) 29 (20.3%)
Flatulence n (%) 78 (40%) 82 (44.6%) 46 (29.1%) 54 (37.8%)
Diarrhoea n (%) 20 (10.3%) 19 (10.3%) 20 (12.7%) 15 (10.6%)
Constipation n (%) 48 (24.6%) 60 (32.6%) 28 (17.7%) 36 (25.2%)
Dry mouth n (%) 71 (36.9%) 80 (43.5%) 53 (33.5%) 53 (37.1%)
Thirst n (%) 34 (17.4%) 39 (21.2%) 29 (18.4%) 40 (28%)
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